Ignite Creation Date:
2024-05-05 @ 9:50 PM
Last Modification Date:
2024-10-26 @ 10:10 AM
Study NCT ID:
NCT00978029
Status:
COMPLETED
Last Update Posted:
2017-03-03
First Post:
2009-09-11
Brief Title:
Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older Study P06081
Sponsor:
ALK-Abelló AS
Organization:
ALK-Abelló AS
Study Overview
Official Title:
A 28-Day Study Evaluating the Safety of Ragweed Ambrosia Artemisiifolia Sublingual Tablet SCH 39641 in Adult Subjects 50 Years of Age and Older With Ragweed-Induced Rhinoconjunctivitis Protocol No P06081
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study was to assess the safety and tolerability of a ragweed allergy immunotherapy tablet AIT administered sublingually under-the tongue in subjects 50 years of age and older with ragweed-induced rhinoconjunctivitis with or without asthma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MK-3641-004 | OTHER | Merck | None |